SOPHiA GENETICS Raises $57.5M in Oversubscribed Share Offering

Event summary

  • SOPHiA GENETICS closed a $57.5M public offering of ordinary shares, including full exercise of underwriters' option for additional shares.
  • The company sold 12,104,900 shares at $4.75 per share, with strong investor demand leading to oversubscription.
  • TD Cowen led the offering as book-running manager, with Guggenheim Securities, BTIG, and Craig-Hallum as co-managers.
  • The offering was registered with the SEC under Form F-3, effective August 15, 2025.

The big picture

SOPHiA GENETICS' successful $57.5M share offering underscores the growing investor interest in AI-driven healthcare solutions. The oversubscription suggests strong confidence in the company's ability to expand access to data-driven medicine, particularly as the precision medicine market continues to evolve. The proceeds will likely be critical in scaling SOPHiA DDM™, its flagship AI platform, amid increasing competition and regulatory scrutiny in the sector.

What we're watching

Capital Deployment
How SOPHiA GENETICS will allocate the $57.5M proceeds to drive growth in its AI-driven precision medicine platform.
Market Positioning
Whether the successful offering signals renewed investor confidence in the precision medicine sector.
Execution Risk
The pace at which the company can translate this funding into tangible clinical and commercial outcomes.